Novavax (NASDAQ:NVAX) Stock Keeps “Buy” Rating at B. Riley Financial

B. Riley Financial restated their buy rating on shares of Novavax (NASDAQ:NVAX) in a research report report published on Friday,Benzinga reports. The brokerage currently has a $16.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $18.00.

Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Novavax in a research report on Tuesday, October 27th. Citigroup restated a “sell” rating and set a $8.00 price objective (up from $7.00) on shares of Novavax in a report on Thursday, October 15th. Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a research note on Monday. Finally, Zacks Research lowered shares of Novavax from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $12.33.

Novavax Stock Up 10.2%

NVAX traded up $1.00 during midday trading on Friday, hitting $10.78. The company had a trading volume of 6,284,977 shares, compared to its average volume of 7,900,039. Novavax has a 52 week low of $6.20 and a 52 week high of $13.39. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -23.43 and a beta of 2.65. The stock’s 50 day moving average price is $10.56 and its 200 day moving average price is $9.35.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.16. The firm had revenue of $68.30 million for the quarter, compared to analyst estimates of $50.42 million. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.25) earnings per share. Research analysts predict that Novavax will post -0.38 EPS for the current year.

Institutional Investors Weigh In On Novavax

A number of institutional investors have recently made changes to their positions in NVAX. KBC Group NV raised its position in Novavax by 34.9% in the 1st quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 1,229 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Novavax by 292.5% during the 2nd quarter. Allworth Financial LP now owns 4,353 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 3,244 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of Novavax during the 2nd quarter valued at about $42,000. Principal Financial Group Inc. bought a new stake in shares of Novavax in the first quarter worth approximately $83,000. Finally, Caxton Associates LLP bought a new stake in shares of Novavax in the first quarter worth approximately $90,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Trending Headlines about Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a Q3 loss of $0.19 per share, narrower than analysts’ expected $0.35 loss, while revenue of $68.3 million topped estimates of about $50.4 million. The loss also improved from $0.62 per share a year earlier. Article: Novavax Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: The company raised its 2026 revenue outlook to $385 million–$415 million, or $400 million at the midpoint—about $145 million higher than its prior framework. A $125 million milestone from Sanofi, earned after a Phase 3 trial launch, accounts for much of the increase. Novavax also reduced operating expenses and said its cash runway extends into 2029. Article: Novavax boosts 2026 revenue forecast as licensing deals pay off
• Neutral Sentiment: B. Riley reaffirmed its Buy rating, though it lowered its price target to $16 from $18. The reduced target tempers the otherwise positive analyst stance. Article: B. Riley stock recommendations
• Negative Sentiment: Investors may be focused on Novavax pushing its profitability target out to 2029. Q3 revenue was still down 3% year over year, and the higher 2026 outlook depends substantially on the Sanofi milestone, raising questions about the durability of revenue growth. Article: Novavax pushes profitability target to 2029, shares dip

About Novavax

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.